DAMORA THERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
DAMORA THERAPEUTICS, INC. (DMRA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $8.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-19
- DAMORA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $8.20M, a 115.79% increase from fiscal 2024.
- DAMORA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $3.80M, a 61.62% decline from fiscal 2023.
- DAMORA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $9.90M, a 41.76% decline from fiscal 2022.
- DAMORA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $17.00M, a 14.86% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $8.20M 10-K · filed 2026-03-19 |
| 2024-12-31 | $3.80M 10-K · filed 2025-03-19 |
| 2023-12-31 | $9.90M 10-K · filed 2024-03-08 |
| 2022-12-31 | $17.00M 10-K · filed 2023-03-09 |
| 2021-12-31 | $14.80M 10-K · filed 2022-02-17 |
| 2020-12-31 | $10.40M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |